Dr. Shirin Shafazand, MD

Dr. Shafazand practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Shafazand's NPI, 1225044738, was assigned on August 1, 2006. Dr. Shafazand graduated from University of Toronto Faculty of Medicine in 1995. Dr. Shafazand holds Florida license ME90260.

Dr. Shafazand's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Shafazand's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Shafazand is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shafazand practices, 2 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Shafazand's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Shafazand is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Shafazand's licenses on file in 3 states: Florida, California and District of Columbia.

Dmand AI lists hypersomnia, pulmonary fibrosis, pulmonary heart disease and sleep apnea among the conditions Dr. Shafazand treats.

CMS data shows 146 Medicare services from Dr. Shafazand across 4 procedure codes in 2024, for 128 Medicare patients. Medicare paid $11,053 for them.

CMS counts 128 Medicare patients who saw Dr. Shafazand in 2024. The largest group is 65 to 74, with 63 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.36, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shafazand's median patient age at 65, with 55% women.

In 2024, Dr. Shafazand wrote 342 Medicare Part D claims for 24 patients. 82% of them were for generic drugs. CMS names the drug for 266 of them, across 5 drugs with 11 or more claims each, at $861,297 in total drug cost. In 2023, CMS named 332 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Shafazand for performance year 2024, reported as part of a group. Dr. Shafazand accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shafazand as offering telehealth.

Dmand AI links 55 papers to Dr. Shafazand, published from 2011 to 2025. 2018 was the busiest year, with 3. The most frequent topics are Sleep Apnea, Obstructive, Continuous Positive Airway Pressure and Hispanic or Latino. Dr. Shafazand has published most often in J Clin Sleep Med. Dr. Shafazand's most frequent co-authors are Douglas McKay Wallace, MD, Alexandre R. Abreu, MD and Salim Ibrahim Dib, MD.

Dmand AI links Dr. Shafazand to 5 clinical trials. 1 is still active or recruiting. Conditions studied include Asthma, Bronchiectasis and Idiopathic Pulmonary Fibrosis. University of Miami sponsors the most, 2. Open Payments lists research payments to Dr. Shafazand that name 1 trial.

CMS Open Payments shows 86 general payments to Dr. Shafazand from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 99% of the total. AstraZeneca Pharmaceuticals LP paid the most, $186,995. It also lists 14 research payments totaling $64,846 from 2016 to 2022, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Shafazand, most recently CMS Stage 1 EHR in 2014.

Dr. Shafazand graduated from University of Toronto Faculty of Medicine in 1995.

Dr. Shafazand is in network with 10 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.